Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Apr 04, 2023 1:43pm

286 Views

Post# 35379182

Efficacy %s = Market shares = Revenues

Big pharmas are all about revenues, earning/share.

One key factor to get them to earning/share is mostly revenues. And revenues are generated by market shares. Technologies that get higher market shares are those that can deliver higher efficacy %s.

TLT's treatment is not placing urologist out of their comfort zone. The equipments (fiber optics) are inserted via the same conduits (urethra) than they're used to. The rest of the process is automated. Instilling TLD-1433 or instilling BCG, that's nothing different, as they are both liquids.

We just need to present higher efficacy numbers than competition and we are in this process. Until p#13, we had disastrous Ph. 2 data. We had to revert this trend and that had to come up with treating more patients to see if the adjustments were appropriate and then, we had to let these new efficacy %s be above competition.